文献速递药物相互作用

羟丙基-β-环糊精对fenebrutinib吸收的影响:伊曲康唑药物相互作用研究解读

Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study.
PubMed 文献 · Clin Pharmacol Ther · 2020-07-18

本研究在伊曲康唑-fenebrutinib药物相互作用研究中发现,伊曲康唑组未出现预期的fenebrutinib血药峰浓度升高,且达峰时间延迟。体外实验显示fenebrutinib与羟丙基-β-环糊精的结合常数为2×10^5 M^-1,且fenebrutinib表观渗透性随环糊精浓度依赖性降低。狗体内实验重复了上述观察,支持环糊精通过包合作用降低fenebrutinib吸收速率和程度的假说。

要点

  • 伊曲康唑口服溶液中的羟丙基-β-环糊精可与fenebrutinib形成包合物,降低其吸收
  • 临床药物相互作用研究中若使用含环糊精的制剂,需考虑辅料对受试药物吸收的潜在影响
  • 环糊精对fenebrutinib吸收的影响表现为Cmax降低和Tmax延迟

核心结论

  • 羟丙基-β-环糊精与fenebrutinib形成包合物,降低fenebrutinib的吸收速率和程度,可解释伊曲康唑药物相互作用研究中未观察到预期的Cmax升高。

研究设计与样本

  • 基于伊曲康唑-fenebrutinib药物相互作用研究的临床观察,结合体外结合实验、MDCK细胞渗透性实验、五肽胃泌素预处理狗模型和基于生理的药代动力学建模。

主要发现

  • 在伊曲康唑组中,相对于对照组,未观察到预期的fenebrutinib Cmax升高,且观察到Tmax延迟。
  • fenebrutinib与羟丙基-β-环糊精的体外结合常数为2×10^5 M^-1。
  • fenebrutinib跨MDCK细胞单层的表观渗透性随环糊精浓度依赖性降低。
  • 在五肽胃泌素预处理的狗模型中,fenebrutinib与环糊精同服导致Cmax降低、Tmax延长和粪便中fenebrutinib回收率增加,重复了健康志愿者中的观察。

临床怎么用

  • 在解读伊曲康唑等含环糊精辅料制剂的药物相互作用研究结果时,应考虑辅料包合受试药物对吸收的影响。
  • 对于与环糊精结合常数较高的药物,使用含环糊精的制剂可能改变其生物利用度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cyclodextrins are widely used pharmaceutical excipients, particularly for insoluble compounds dosed orally, such as the oral solution of itraconazole, which is frequently used in clinical drug-drug interaction studies to inhibit cytochrome P450 3A. Since cyclodextrins act by forming inclusion complexes with their coformulated drug, they could have an unintended consequence of affecting absorption if they form a strong complex with the potential victim drug in an itraconazole drug-drug interaction study. This observation was made in a drug-drug interaction study with the Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib and itraconazole, in which, relative to the control group, the expected increase in fenebrutinib maximum plasma concentration (Cmax ) was not observed in the itraconazole group, and a delay in time to reach maximum plasma concentration (Tmax ) was observed in the itraconazole group. The in vitro binding constant between fenebrutinib and hydroxypropyl-β-cyclodextrin was determined to be 2 × 105 M-1 , and the apparent permeability of fenebrutinib across a Madin-Darby canine kidney cell monolayer decreased in a cyclodextrin concentration-dependent manner. This observation was confirmed in vivo, in a pentagastrin-pretreated dog model, in which fenebrutinib was administered with or without cyclodextrin; a reduction in Cmax , a prolonged Tmax , and increased fenebrutinib recovery in feces replicated the previous observation in healthy volunteers and supported the hypothesis that complexation with cyclodextrin decreased rate and extent of fenebrutinib absorption. Physiologically-based pharmacokinetic modeling was used to translate the in vitro effect of cyclodextrin on fenebrutinib apparent permeability to the in vivo effect on absorption, which was then confirmed using the in vivo dog pharmacokinetic data.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Durk MR, Jones NS, Liu J, et al. Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study. Clin Pharmacol Ther. 2020. PMID: 32535897. doi:10.1002/cpt.1943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。